#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The gut microbiota is an ecological community constituted by a large number of bacteria , archaea , protists , fungi and viruses .
3-1	17-20	The	abstract[4]	new[4]	coref	3-5[5_4]
3-2	21-24	gut	abstract|abstract[4]	new|new[4]	coref	5-10
3-3	25-35	microbiota	abstract[4]	new[4]	_	_
3-4	36-38	is	_	_	_	_
3-5	39-41	an	abstract[5]	giv[5]	coref	4-1[12_5]
3-6	42-52	ecological	abstract[5]	giv[5]	_	_
3-7	53-62	community	abstract[5]	giv[5]	_	_
3-8	63-74	constituted	_	_	_	_
3-9	75-77	by	_	_	_	_
3-10	78-79	a	abstract[6]	new[6]	_	_
3-11	80-85	large	abstract[6]	new[6]	_	_
3-12	86-92	number	abstract[6]	new[6]	_	_
3-13	93-95	of	abstract[6]	new[6]	_	_
3-14	96-104	bacteria	abstract[6]|animal	new[6]|new	coref	9-14[45_0]
3-15	105-106	,	abstract[6]	new[6]	_	_
3-16	107-114	archaea	abstract[6]|animal	new[6]|new	_	_
3-17	115-116	,	abstract[6]	new[6]	_	_
3-18	117-125	protists	abstract[6]|person	new[6]|new	_	_
3-19	126-127	,	abstract[6]	new[6]	_	_
3-20	128-133	fungi	abstract[6]|object	new[6]|new	_	_
3-21	134-137	and	abstract[6]	new[6]	_	_
3-22	138-145	viruses	abstract[6]|object	new[6]|new	_	_
3-23	146-147	.	_	_	_	_

#Text=The microbiota produces multiple metabolites that may cross the intestinal barrier and exert biological effects .
4-1	148-151	The	abstract[12]	giv[12]	coref	5-1[17_12]
4-2	152-162	microbiota	abstract[12]	giv[12]	_	_
4-3	163-171	produces	_	_	_	_
4-4	172-180	multiple	object[13]	new[13]	_	_
4-5	181-192	metabolites	object[13]	new[13]	_	_
4-6	193-197	that	_	_	_	_
4-7	198-201	may	_	_	_	_
4-8	202-207	cross	_	_	_	_
4-9	208-211	the	object[15]	new[15]	coref	5-9[20_15]
4-10	212-222	intestinal	abstract|object[15]	new|new[15]	_	_
4-11	223-230	barrier	object[15]	new[15]	_	_
4-12	231-234	and	_	_	_	_
4-13	235-240	exert	_	_	_	_
4-14	241-251	biological	abstract[16]	new[16]	coref	19-16[150_16]
4-15	252-259	effects	abstract[16]	new[16]	_	_
4-16	260-261	.	_	_	_	_

#Text=The microbiota also impacts on the integrity of the gut barrier .
5-1	262-265	The	abstract[17]	giv[17]	coref	7-8[32_17]
5-2	266-276	microbiota	abstract[17]	giv[17]	_	_
5-3	277-281	also	_	_	_	_
5-4	282-289	impacts	_	_	_	_
5-5	290-292	on	_	_	_	_
5-6	293-296	the	abstract[18]	new[18]	_	_
5-7	297-306	integrity	abstract[18]	new[18]	_	_
5-8	307-309	of	abstract[18]	new[18]	_	_
5-9	310-313	the	abstract[18]|object[20]	new[18]|giv[20]	coref	6-2[0_20]
5-10	314-317	gut	abstract[18]|abstract|object[20]	new[18]|giv|giv[20]	coref	10-35
5-11	318-325	barrier	abstract[18]|object[20]	new[18]|giv[20]	_	_
5-12	326-327	.	_	_	_	_

#Text=Gut barrier dysfunction may result in bacterial translocation from the intestines with increased plasma lipopolysaccharides ( LPS ) .
6-1	328-331	Gut	person|abstract[23]	new|new[23]	coref|coref	8-1|8-1
6-2	332-339	barrier	object|abstract[23]	giv|new[23]	_	_
6-3	340-351	dysfunction	abstract[23]	new[23]	_	_
6-4	352-355	may	_	_	_	_
6-5	356-362	result	_	_	_	_
6-6	363-365	in	_	_	_	_
6-7	366-375	bacterial	substance|abstract[25]	new|new[25]	_	_
6-8	376-389	translocation	abstract[25]	new[25]	_	_
6-9	390-394	from	_	_	_	_
6-10	395-398	the	place[26]	new[26]	_	_
6-11	399-409	intestines	place[26]	new[26]	_	_
6-12	410-414	with	place[26]	new[26]	_	_
6-13	415-424	increased	place[26]|substance[28]	new[26]|new[28]	_	_
6-14	425-431	plasma	place[26]|abstract|substance[28]	new[26]|new|new[28]	_	_
6-15	432-451	lipopolysaccharides	place[26]|substance[28]	new[26]|new[28]	_	_
6-16	452-453	(	_	_	_	_
6-17	454-457	LPS	object	new	_	_
6-18	458-459	)	_	_	_	_
6-19	460-461	.	_	_	_	_

#Text=Multiple studies have found a relationship between the microbiota and adequate metabolic , hormonal and immunologic homeostasis .
7-1	462-470	Multiple	event[30]	new[30]	_	_
7-2	471-478	studies	event[30]	new[30]	_	_
7-3	479-483	have	_	_	_	_
7-4	484-489	found	_	_	_	_
7-5	490-491	a	abstract[31]	new[31]	_	_
7-6	492-504	relationship	abstract[31]	new[31]	_	_
7-7	505-512	between	abstract[31]	new[31]	_	_
7-8	513-516	the	abstract[31]|abstract[32]	new[31]|giv[32]	coref	8-11[38_32]
7-9	517-527	microbiota	abstract[31]|abstract[32]	new[31]|giv[32]	_	_
7-10	528-531	and	abstract[31]	new[31]	_	_
7-11	532-540	adequate	abstract[31]|abstract[33]	new[31]|new[33]	coref	10-1[50_33]
7-12	541-550	metabolic	abstract[31]|abstract[33]	new[31]|new[33]	_	_
7-13	551-552	,	abstract[31]	new[31]	_	_
7-14	553-561	hormonal	abstract[31]|abstract[34]	new[31]|new[34]	coref	15-10[118_34]
7-15	562-565	and	abstract[31]|abstract[34]	new[31]|new[34]	_	_
7-16	566-577	immunologic	abstract[31]|abstract[34]	new[31]|new[34]	_	_
7-17	578-589	homeostasis	abstract[31]|abstract[34]	new[31]|new[34]	_	_
7-18	590-591	.	_	_	_	_

#Text=Gut dysbiosis , i. e. , an altered composition of the intestinal microbiota in disease is associated with poor health outcomes .
8-1	592-595	Gut	person|abstract[36]	giv|new[36]	coref|coref	9-1[0_36]|9-1[0_36]
8-2	596-605	dysbiosis	abstract[36]	new[36]	_	_
8-3	606-607	,	_	_	_	_
8-4	608-610	i.	_	_	_	_
8-5	611-613	e.	_	_	_	_
8-6	614-615	,	_	_	_	_
8-7	616-618	an	abstract[37]	new[37]	_	_
8-8	619-626	altered	abstract[37]	new[37]	_	_
8-9	627-638	composition	abstract[37]	new[37]	_	_
8-10	639-641	of	abstract[37]	new[37]	_	_
8-11	642-645	the	abstract[37]|abstract[38]	new[37]|giv[38]	coref	9-24[49_38]
8-12	646-656	intestinal	abstract[37]|abstract[38]	new[37]|giv[38]	_	_
8-13	657-667	microbiota	abstract[37]|abstract[38]	new[37]|giv[38]	_	_
8-14	668-670	in	abstract[37]|abstract[38]	new[37]|giv[38]	_	_
8-15	671-678	disease	abstract[37]|abstract[38]|abstract	new[37]|giv[38]|new	_	_
8-16	679-681	is	_	_	_	_
8-17	682-692	associated	_	_	_	_
8-18	693-697	with	_	_	_	_
8-19	698-702	poor	abstract[41]	new[41]	_	_
8-20	703-709	health	abstract|abstract[41]	new|new[41]	_	_
8-21	710-718	outcomes	abstract[41]	new[41]	_	_
8-22	719-720	.	_	_	_	_

#Text=Dysbiosis may be treated with probiotics , i. e. , live strains of selected bacteria , or prebiotics , food components that modulate the microbiota .
9-1	721-730	Dysbiosis	abstract	giv	coref	11-1
9-2	731-734	may	_	_	_	_
9-3	735-737	be	_	_	_	_
9-4	738-745	treated	_	_	_	_
9-5	746-750	with	_	_	_	_
9-6	751-761	probiotics	substance	new	_	_
9-7	762-763	,	_	_	_	_
9-8	764-766	i.	_	_	_	_
9-9	767-769	e.	_	_	_	_
9-10	770-771	,	_	_	_	_
9-11	772-776	live	abstract[44]	new[44]	_	_
9-12	777-784	strains	abstract[44]	new[44]	_	_
9-13	785-787	of	abstract[44]	new[44]	_	_
9-14	788-796	selected	abstract[44]|animal[45]	new[44]|giv[45]	coref	11-51[79_45]
9-15	797-805	bacteria	abstract[44]|animal[45]	new[44]|giv[45]	_	_
9-16	806-807	,	_	_	_	_
9-17	808-810	or	_	_	_	_
9-18	811-821	prebiotics	substance	new	_	_
9-19	822-823	,	_	_	_	_
9-20	824-828	food	object|substance[48]	new|new[48]	_	_
9-21	829-839	components	substance[48]	new[48]	_	_
9-22	840-844	that	_	_	_	_
9-23	845-853	modulate	_	_	_	_
9-24	854-857	the	abstract[49]	giv[49]	coref	10-34[65_49]
9-25	858-868	microbiota	abstract[49]	giv[49]	_	_
9-26	869-870	.	_	_	_	_

#Text=Multiple metabolic , cardiovascular , and respiratory diseases including type 2 diabetes mellitus , obesity , systemic and pulmonary hypertension , atherosclerosis , heart failure and chronic respiratory diseases have been linked to impaired gut microbiota .
10-1	871-879	Multiple	abstract[50]	giv[50]	_	_
10-2	880-889	metabolic	abstract[50]	giv[50]	_	_
10-3	890-891	,	_	_	_	_
10-4	892-906	cardiovascular	abstract	new	_	_
10-5	907-908	,	_	_	_	_
10-6	909-912	and	_	_	_	_
10-7	913-924	respiratory	abstract[52]	new[52]	_	_
10-8	925-933	diseases	abstract[52]	new[52]	_	_
10-9	934-943	including	abstract[52]	new[52]	_	_
10-10	944-948	type	abstract[52]|abstract	new[52]|new	_	_
10-11	949-950	2	abstract[55]	new[55]	_	_
10-12	951-959	diabetes	abstract|abstract[55]	new|new[55]	_	_
10-13	960-968	mellitus	abstract[55]	new[55]	_	_
10-14	969-970	,	_	_	_	_
10-15	971-978	obesity	abstract	new	_	_
10-16	979-980	,	_	_	_	_
10-17	981-989	systemic	_	_	_	_
10-18	990-993	and	_	_	_	_
10-19	994-1003	pulmonary	person	new	_	_
10-20	1004-1016	hypertension	abstract	new	_	_
10-21	1017-1018	,	_	_	_	_
10-22	1019-1034	atherosclerosis	abstract	new	_	_
10-23	1035-1036	,	_	_	_	_
10-24	1037-1042	heart	object|abstract[61]	new|new[61]	_	_
10-25	1043-1050	failure	abstract[61]	new[61]	_	_
10-26	1051-1054	and	_	_	_	_
10-27	1055-1062	chronic	abstract[63]	new[63]	coref	16-15[132_63]
10-28	1063-1074	respiratory	object|abstract[63]	new|new[63]	coref	16-13
10-29	1075-1083	diseases	abstract[63]	new[63]	_	_
10-30	1084-1088	have	_	_	_	_
10-31	1089-1093	been	_	_	_	_
10-32	1094-1100	linked	_	_	_	_
10-33	1101-1103	to	_	_	_	_
10-34	1104-1112	impaired	abstract[65]	giv[65]	coref	20-12[159_65]
10-35	1113-1116	gut	abstract|abstract[65]	giv|giv[65]	coref	20-13
10-36	1117-1127	microbiota	abstract[65]	giv[65]	_	_
10-37	1128-1129	.	_	_	_	_

#Text=Dysbiosis is frequently characterized by : ( a ) lower microbial diversity and richness , ( b ) changes in the relative abundance of phyla with an increased Firmicutes to Bacteroidetes ratio ( F/B ) , and ( c ) changes in short chain fatty acids ( SCFA ) producing bacteria with a relative increase in lactate-producing bacteria and a relative decrease in acetate- and butyrate-producing bacteria .
11-1	1130-1139	Dysbiosis	event	giv	_	_
11-2	1140-1142	is	_	_	_	_
11-3	1143-1153	frequently	_	_	_	_
11-4	1154-1167	characterized	_	_	_	_
11-5	1168-1170	by	_	_	_	_
11-6	1171-1172	:	_	_	_	_
11-7	1173-1174	(	abstract[67]	new[67]	_	_
11-8	1175-1176	a	abstract[67]	new[67]	_	_
11-9	1177-1178	)	abstract[67]	new[67]	_	_
11-10	1179-1184	lower	abstract[67]	new[67]	_	_
11-11	1185-1194	microbial	abstract[67]	new[67]	_	_
11-12	1195-1204	diversity	abstract[67]	new[67]	_	_
11-13	1205-1208	and	_	_	_	_
11-14	1209-1217	richness	abstract	new	_	_
11-15	1218-1219	,	_	_	_	_
11-16	1220-1221	(	_	_	_	_
11-17	1222-1223	b	place	new	_	_
11-18	1224-1225	)	_	_	_	_
11-19	1226-1233	changes	_	_	_	_
11-20	1234-1236	in	_	_	_	_
11-21	1237-1240	the	abstract[70]	new[70]	_	_
11-22	1241-1249	relative	abstract[70]	new[70]	_	_
11-23	1250-1259	abundance	abstract[70]	new[70]	_	_
11-24	1260-1262	of	abstract[70]	new[70]	_	_
11-25	1263-1268	phyla	abstract[70]|abstract	new[70]|new	_	_
11-26	1269-1273	with	abstract[70]	new[70]	_	_
11-27	1274-1276	an	abstract[70]|abstract[72]	new[70]|new[72]	_	_
11-28	1277-1286	increased	abstract[70]|abstract[72]	new[70]|new[72]	_	_
11-29	1287-1297	Firmicutes	abstract[70]|abstract[72]	new[70]|new[72]	_	_
11-30	1298-1300	to	abstract[70]|abstract[72]	new[70]|new[72]	_	_
11-31	1301-1314	Bacteroidetes	abstract[70]|abstract[72]|person|abstract[74]	new[70]|new[72]|new|new[74]	appos|appos	11-34[0_74]|11-34[0_74]
11-32	1315-1320	ratio	abstract[70]|abstract[72]|abstract[74]	new[70]|new[72]|new[74]	_	_
11-33	1321-1322	(	_	_	_	_
11-34	1323-1326	F/B	abstract	giv	_	_
11-35	1327-1328	)	_	_	_	_
11-36	1329-1330	,	_	_	_	_
11-37	1331-1334	and	_	_	_	_
11-38	1335-1336	(	_	_	_	_
11-39	1337-1338	c	abstract	new	_	_
11-40	1339-1340	)	_	_	_	_
11-41	1341-1348	changes	_	_	_	_
11-42	1349-1351	in	_	_	_	_
11-43	1352-1357	short	abstract[77]	new[77]	appos	11-48[0_77]
11-44	1358-1363	chain	abstract[77]	new[77]	_	_
11-45	1364-1369	fatty	abstract[77]	new[77]	_	_
11-46	1370-1375	acids	abstract[77]	new[77]	_	_
11-47	1376-1377	(	_	_	_	_
11-48	1378-1382	SCFA	abstract	giv	_	_
11-49	1383-1384	)	_	_	_	_
11-50	1385-1394	producing	_	_	_	_
11-51	1395-1403	bacteria	animal[79]	giv[79]	_	_
11-52	1404-1408	with	animal[79]	giv[79]	_	_
11-53	1409-1410	a	animal[79]|abstract[80]	giv[79]|new[80]	_	_
11-54	1411-1419	relative	animal[79]|abstract[80]	giv[79]|new[80]	_	_
11-55	1420-1428	increase	animal[79]|abstract[80]	giv[79]|new[80]	_	_
11-56	1429-1431	in	animal[79]|abstract[80]	giv[79]|new[80]	_	_
11-57	1432-1449	lactate-producing	animal[79]|abstract[80]	giv[79]|new[80]	_	_
11-58	1450-1458	bacteria	animal[79]|abstract[80]	giv[79]|new[80]	_	_
11-59	1459-1462	and	animal[79]|abstract[80]	giv[79]|new[80]	_	_
11-60	1463-1464	a	animal[79]|abstract[80]|event[81]	giv[79]|new[80]|new[81]	_	_
11-61	1465-1473	relative	animal[79]|abstract[80]|event[81]	giv[79]|new[80]|new[81]	_	_
11-62	1474-1482	decrease	animal[79]|abstract[80]|event[81]	giv[79]|new[80]|new[81]	_	_
11-63	1483-1485	in	animal[79]|abstract[80]|event[81]	giv[79]|new[80]|new[81]	_	_
11-64	1486-1494	acetate-	animal[79]|abstract[80]|event[81]	giv[79]|new[80]|new[81]	_	_
11-65	1495-1498	and	animal[79]|abstract[80]|event[81]	giv[79]|new[80]|new[81]	_	_
11-66	1499-1517	butyrate-producing	animal[79]|abstract[80]|event[81]	giv[79]|new[80]|new[81]	_	_
11-67	1518-1526	bacteria	animal[79]|abstract[80]|event[81]	giv[79]|new[80]|new[81]	_	_
11-68	1527-1528	.	_	_	_	_

#Text=Vitamin D is produced from dermal exposure to sunlight or from the diet and is converted in the liver into 25-OH-cholecaciferol or calcifediol ( 25OHVitD ) , whose measure serves as an indicator of the vitamin D status .
12-1	1529-1536	Vitamin	substance	new	coref	12-36
12-2	1537-1538	D	person	new	coref	12-37
12-3	1539-1541	is	_	_	_	_
12-4	1542-1550	produced	_	_	_	_
12-5	1551-1555	from	_	_	_	_
12-6	1556-1562	dermal	animal|abstract[85]	new|new[85]	coref|coref	14-17[112_85]|14-17[112_85]
12-7	1563-1571	exposure	abstract[85]	new[85]	_	_
12-8	1572-1574	to	abstract[85]	new[85]	_	_
12-9	1575-1583	sunlight	abstract[85]|substance	new[85]|new	_	_
12-10	1584-1586	or	_	_	_	_
12-11	1587-1591	from	_	_	_	_
12-12	1592-1595	the	substance[87]	new[87]	_	_
12-13	1596-1600	diet	substance[87]	new[87]	_	_
12-14	1601-1604	and	_	_	_	_
12-15	1605-1607	is	_	_	_	_
12-16	1608-1617	converted	_	_	_	_
12-17	1618-1620	in	_	_	_	_
12-18	1621-1624	the	object[88]	new[88]	_	_
12-19	1625-1630	liver	object[88]	new[88]	_	_
12-20	1631-1635	into	object[88]	new[88]	_	_
12-21	1636-1656	25-OH-cholecaciferol	object[88]|quantity	new[88]|new	_	_
12-22	1657-1659	or	object[88]	new[88]	_	_
12-23	1660-1671	calcifediol	object[88]	new[88]	_	_
12-24	1672-1673	(	object[88]	new[88]	_	_
12-25	1674-1682	25OHVitD	object[88]|quantity	new[88]|new	_	_
12-26	1683-1684	)	object[88]	new[88]	_	_
12-27	1685-1686	,	_	_	_	_
12-28	1687-1692	whose	abstract[91]	new[91]	_	_
12-29	1693-1700	measure	abstract[91]	new[91]	_	_
12-30	1701-1707	serves	_	_	_	_
12-31	1708-1710	as	_	_	_	_
12-32	1711-1713	an	_	_	_	_
12-33	1714-1723	indicator	_	_	_	_
12-34	1724-1726	of	_	_	_	_
12-35	1727-1730	the	abstract[94]	new[94]	_	_
12-36	1731-1738	vitamin	substance|abstract[94]	giv|new[94]	ana	13-1
12-37	1739-1740	D	person|abstract[94]	giv|new[94]	coref	13-25
12-38	1741-1747	status	abstract[94]	new[94]	_	_
12-39	1748-1749	.	_	_	_	_

#Text=This is further metabolized mainly in the kidney into 1-α,25-dihydroxycholecalciferol , the most active form , also named calcitriol , which activates the vitamin D receptor ( VDR ) .
13-1	1750-1754	This	substance	giv	coref	13-24
13-2	1755-1757	is	_	_	_	_
13-3	1758-1765	further	_	_	_	_
13-4	1766-1777	metabolized	_	_	_	_
13-5	1778-1784	mainly	_	_	_	_
13-6	1785-1787	in	_	_	_	_
13-7	1788-1791	the	place[96]	new[96]	_	_
13-8	1792-1798	kidney	place[96]	new[96]	_	_
13-9	1799-1803	into	_	_	_	_
13-10	1804-1835	1-α,25-dihydroxycholecalciferol	quantity	new	_	_
13-11	1836-1837	,	_	_	_	_
13-12	1838-1841	the	substance[98]	new[98]	_	_
13-13	1842-1846	most	substance[98]	new[98]	_	_
13-14	1847-1853	active	substance[98]	new[98]	_	_
13-15	1854-1858	form	substance[98]	new[98]	_	_
13-16	1859-1860	,	_	_	_	_
13-17	1861-1865	also	_	_	_	_
13-18	1866-1871	named	_	_	_	_
13-19	1872-1882	calcitriol	substance	new	coref	17-9
13-20	1883-1884	,	_	_	_	_
13-21	1885-1890	which	_	_	_	_
13-22	1891-1900	activates	_	_	_	_
13-23	1901-1904	the	substance[102]	new[102]	_	_
13-24	1905-1912	vitamin	substance|substance[102]	giv|new[102]	coref	14-1
13-25	1913-1914	D	person|substance[102]	giv|new[102]	coref	14-2
13-26	1915-1923	receptor	substance[102]	new[102]	_	_
13-27	1924-1925	(	_	_	_	_
13-28	1926-1929	VDR	abstract	new	coref	17-12
13-29	1930-1931	)	_	_	_	_
13-30	1932-1933	.	_	_	_	_

#Text=Vitamin D deficiency , which causes rickets and osteomalacia , is very common worldwide due to insufficient solar light exposure and/or a reduced dietary intake .
14-1	1934-1941	Vitamin	substance|abstract[106]	giv|new[106]	coref|coref|coref|coref	14-12[109_106]|15-13|14-12[109_106]|15-13
14-2	1942-1943	D	person|abstract[106]	giv|new[106]	coref	15-13[120_0]
14-3	1944-1954	deficiency	abstract[106]	new[106]	_	_
14-4	1955-1956	,	_	_	_	_
14-5	1957-1962	which	_	_	_	_
14-6	1963-1969	causes	_	_	_	_
14-7	1970-1977	rickets	abstract	new	_	_
14-8	1978-1981	and	_	_	_	_
14-9	1982-1994	osteomalacia	abstract	new	_	_
14-10	1995-1996	,	_	_	_	_
14-11	1997-1999	is	_	_	_	_
14-12	2000-2004	very	abstract[109]	giv[109]	coref	16-1[128_109]
14-13	2005-2011	common	abstract[109]	giv[109]	_	_
14-14	2012-2021	worldwide	abstract[109]	giv[109]	_	_
14-15	2022-2025	due	abstract[109]	giv[109]	_	_
14-16	2026-2028	to	_	_	_	_
14-17	2029-2041	insufficient	abstract[112]	giv[112]	_	_
14-18	2042-2047	solar	person|abstract[112]	new|giv[112]	_	_
14-19	2048-2053	light	abstract|abstract[112]	new|giv[112]	_	_
14-20	2054-2062	exposure	abstract[112]	giv[112]	_	_
14-21	2063-2069	and/or	abstract[112]	giv[112]	_	_
14-22	2070-2071	a	abstract[112]|event[114]	giv[112]|new[114]	_	_
14-23	2072-2079	reduced	abstract[112]|event[114]	giv[112]|new[114]	_	_
14-24	2080-2087	dietary	abstract[112]|abstract|event[114]	giv[112]|new|new[114]	_	_
14-25	2088-2094	intake	abstract[112]|event[114]	giv[112]|new[114]	_	_
14-26	2095-2096	.	_	_	_	_

#Text=Besides this well-known regulatory role in the calcium-phosphorus and bone homeostasis , vitamin D is also involved in the control of other physiological processes , such as cellular growth , intracellular metabolism and innate and adaptive immunity .
15-1	2097-2104	Besides	_	_	_	_
15-2	2105-2109	this	abstract[115]	new[115]	_	_
15-3	2110-2120	well-known	abstract[115]	new[115]	_	_
15-4	2121-2131	regulatory	abstract[115]	new[115]	_	_
15-5	2132-2136	role	abstract[115]	new[115]	_	_
15-6	2137-2139	in	abstract[115]	new[115]	_	_
15-7	2140-2143	the	abstract[115]|substance[116]	new[115]|new[116]	_	_
15-8	2144-2162	calcium-phosphorus	abstract[115]|substance[116]	new[115]|new[116]	_	_
15-9	2163-2166	and	abstract[115]	new[115]	_	_
15-10	2167-2171	bone	abstract[115]|object|abstract[118]	new[115]|new|giv[118]	_	_
15-11	2172-2183	homeostasis	abstract[115]|abstract[118]	new[115]|giv[118]	_	_
15-12	2184-2185	,	_	_	_	_
15-13	2186-2193	vitamin	substance|person[120]	giv|giv[120]	coref|coref|coref|coref	16-1|16-2[0_120]|16-1|16-2[0_120]
15-14	2194-2195	D	person[120]	giv[120]	_	_
15-15	2196-2198	is	_	_	_	_
15-16	2199-2203	also	_	_	_	_
15-17	2204-2212	involved	_	_	_	_
15-18	2213-2215	in	_	_	_	_
15-19	2216-2219	the	abstract[121]	new[121]	_	_
15-20	2220-2227	control	abstract[121]	new[121]	_	_
15-21	2228-2230	of	abstract[121]	new[121]	_	_
15-22	2231-2236	other	abstract[121]|abstract[122]	new[121]|new[122]	_	_
15-23	2237-2250	physiological	abstract[121]|abstract[122]	new[121]|new[122]	_	_
15-24	2251-2260	processes	abstract[121]|abstract[122]	new[121]|new[122]	_	_
15-25	2261-2262	,	abstract[121]	new[121]	_	_
15-26	2263-2267	such	abstract[121]	new[121]	_	_
15-27	2268-2270	as	abstract[121]	new[121]	_	_
15-28	2271-2279	cellular	abstract[121]|abstract[123]	new[121]|new[123]	_	_
15-29	2280-2286	growth	abstract[121]|abstract[123]	new[121]|new[123]	_	_
15-30	2287-2288	,	abstract[121]	new[121]	_	_
15-31	2289-2302	intracellular	abstract[121]|abstract[124]	new[121]|new[124]	_	_
15-32	2303-2313	metabolism	abstract[121]|abstract[124]	new[121]|new[124]	_	_
15-33	2314-2317	and	abstract[121]	new[121]	_	_
15-34	2318-2324	innate	abstract[121]|abstract[125]	new[121]|new[125]	_	_
15-35	2325-2328	and	abstract[121]|abstract[125]	new[121]|new[125]	_	_
15-36	2329-2337	adaptive	abstract[121]|abstract[125]	new[121]|new[125]	_	_
15-37	2338-2346	immunity	abstract[121]|abstract[125]	new[121]|new[125]	_	_
15-38	2347-2348	.	_	_	_	_

#Text=Vitamin D deficiency has also been related to infection , cancer and respiratory and cardiovascular diseases .
16-1	2349-2356	Vitamin	substance|abstract[128]	giv|giv[128]	coref|coref|coref|coref	18-3|20-4[154_128]|18-3|20-4[154_128]
16-2	2357-2358	D	person|abstract[128]	giv|giv[128]	coref	18-3[138_0]
16-3	2359-2369	deficiency	abstract[128]	giv[128]	_	_
16-4	2370-2373	has	_	_	_	_
16-5	2374-2378	also	_	_	_	_
16-6	2379-2383	been	_	_	_	_
16-7	2384-2391	related	_	_	_	_
16-8	2392-2394	to	_	_	_	_
16-9	2395-2404	infection	event	new	_	_
16-10	2405-2406	,	_	_	_	_
16-11	2407-2413	cancer	event	new	_	_
16-12	2414-2417	and	_	_	_	_
16-13	2418-2429	respiratory	abstract	giv	_	_
16-14	2430-2433	and	_	_	_	_
16-15	2434-2448	cardiovascular	abstract[132]	giv[132]	_	_
16-16	2449-2457	diseases	abstract[132]	giv[132]	_	_
16-17	2458-2459	.	_	_	_	_

#Text=Immune cells and peripheral tissues can also synthetize calcitriol and express VDR .
17-1	2460-2466	Immune	object[133]	new[133]	_	_
17-2	2467-2472	cells	object[133]	new[133]	_	_
17-3	2473-2476	and	_	_	_	_
17-4	2477-2487	peripheral	object[134]	new[134]	_	_
17-5	2488-2495	tissues	object[134]	new[134]	_	_
17-6	2496-2499	can	_	_	_	_
17-7	2500-2504	also	_	_	_	_
17-8	2505-2515	synthetize	_	_	_	_
17-9	2516-2526	calcitriol	substance	giv	_	_
17-10	2527-2530	and	_	_	_	_
17-11	2531-2538	express	_	_	_	_
17-12	2539-2542	VDR	abstract	giv	_	_
17-13	2543-2544	.	_	_	_	_

#Text=Thus , vitamin D has been proposed to have immunomodulatory properties and insufficient vitamin D levels may lead to dysregulation of immune responses .
18-1	2545-2549	Thus	_	_	_	_
18-2	2550-2551	,	_	_	_	_
18-3	2552-2559	vitamin	substance|person[138]	giv|giv[138]	coref|coref|coref|coref	18-14|18-15[0_138]|18-14|18-15[0_138]
18-4	2560-2561	D	person[138]	giv[138]	_	_
18-5	2562-2565	has	_	_	_	_
18-6	2566-2570	been	_	_	_	_
18-7	2571-2579	proposed	_	_	_	_
18-8	2580-2582	to	_	_	_	_
18-9	2583-2587	have	_	_	_	_
18-10	2588-2604	immunomodulatory	abstract[139]	new[139]	_	_
18-11	2605-2615	properties	abstract[139]	new[139]	_	_
18-12	2616-2619	and	_	_	_	_
18-13	2620-2632	insufficient	abstract[142]	new[142]	_	_
18-14	2633-2640	vitamin	substance|abstract[142]	giv|new[142]	coref	19-3[146_0]
18-15	2641-2642	D	person|abstract[142]	giv|new[142]	coref	20-7[156_0]
18-16	2643-2649	levels	abstract[142]	new[142]	_	_
18-17	2650-2653	may	_	_	_	_
18-18	2654-2658	lead	_	_	_	_
18-19	2659-2661	to	_	_	_	_
18-20	2662-2675	dysregulation	event[143]	new[143]	_	_
18-21	2676-2678	of	event[143]	new[143]	_	_
18-22	2679-2685	immune	event[143]|abstract|abstract[145]	new[143]|new|new[145]	_	_
18-23	2686-2695	responses	event[143]|abstract[145]	new[143]|new[145]	_	_
18-24	2696-2697	.	_	_	_	_

#Text=Moreover , vitamin D is able to induce the expression of antibacterial proteins and exert antibiotic effects in a variety of cell types .
19-1	2698-2706	Moreover	_	_	_	_
19-2	2707-2708	,	_	_	_	_
19-3	2709-2716	vitamin	substance[146]	giv[146]	coref	20-7[0_146]
19-4	2717-2718	D	substance[146]	giv[146]	_	_
19-5	2719-2721	is	_	_	_	_
19-6	2722-2726	able	_	_	_	_
19-7	2727-2729	to	_	_	_	_
19-8	2730-2736	induce	_	_	_	_
19-9	2737-2740	the	event[147]	new[147]	_	_
19-10	2741-2751	expression	event[147]	new[147]	_	_
19-11	2752-2754	of	event[147]	new[147]	_	_
19-12	2755-2768	antibacterial	event[147]|substance[148]	new[147]|new[148]	_	_
19-13	2769-2777	proteins	event[147]|substance[148]	new[147]|new[148]	_	_
19-14	2778-2781	and	_	_	_	_
19-15	2782-2787	exert	_	_	_	_
19-16	2788-2798	antibiotic	substance|abstract[150]	new|giv[150]	_	_
19-17	2799-2806	effects	abstract[150]	giv[150]	_	_
19-18	2807-2809	in	_	_	_	_
19-19	2810-2811	a	abstract[151]	new[151]	_	_
19-20	2812-2819	variety	abstract[151]	new[151]	_	_
19-21	2820-2822	of	abstract[151]	new[151]	_	_
19-22	2823-2827	cell	abstract[151]|place[152]	new[151]|new[152]	_	_
19-23	2828-2833	types	abstract[151]|place[152]	new[151]|new[152]	_	_
19-24	2834-2835	.	_	_	_	_

#Text=We hypothesized that a deficiency in vitamin D induces changes in the gut microbiota .
20-1	2836-2838	We	person	acc	_	_
20-2	2839-2851	hypothesized	_	_	_	_
20-3	2852-2856	that	_	_	_	_
20-4	2857-2858	a	abstract[154]	giv[154]	_	_
20-5	2859-2869	deficiency	abstract[154]	giv[154]	_	_
20-6	2870-2872	in	abstract[154]	giv[154]	_	_
20-7	2873-2880	vitamin	abstract[154]|substance|substance[156]	giv[154]|giv|giv[156]	_	_
20-8	2881-2882	D	abstract[154]|substance[156]	giv[154]|giv[156]	_	_
20-9	2883-2890	induces	_	_	_	_
20-10	2891-2898	changes	abstract	new	_	_
20-11	2899-2901	in	_	_	_	_
20-12	2902-2905	the	abstract[159]	giv[159]	_	_
20-13	2906-2909	gut	abstract|abstract[159]	giv|giv[159]	_	_
20-14	2910-2920	microbiota	abstract[159]	giv[159]	_	_
20-15	2921-2922	.	_	_	_	_
